Michael Shipman, CEO, is a biomedical researcher completing his Master’s in Biomedical Technology at Syracuse University, where his work integrates plant tissue culture, phyto‑biochemistry, molecular genetics, and climate‑driven disease ecology. As a graduate research assistant with SUNY ESF’s American Chestnut Restoration Project, he contributes to advancing pathogen resistance in chestnut and beech species through molecular approaches and cultivation techniques. His research emphasizes the regulation of human genetic biomarkers via plant derivatives, therapeutic food and device innovation, and the development of sustainable agricultural practices that address global challenges in disease resilience and resource management.
Green Genes is the platform through which Michael translates this research into products that support chronic illness management and disease prevention using natural delivery systems. He also consults on scientific and career networking and organizes unconventional outreach events, such as Skydiving for Science, which raises awareness of aeromicrobiology and pathogen dispersal, including the spread of Coccidioides spp. that causes Valley Fever. These initiatives reflect his commitment to bridging rigorous research with public engagement and innovative solutions for health and sustainability.
Andrew Snowball, Chair of the Board, is a Chartered Civil Engineer and experienced industry leader who brings versatility, engineering acumen, and a passion for learning to his role as Board Chair of Green Genes Therapeutics. Alongside his professional career, Andrew serves as Regional Chair for the Institution of Structural Engineers and as a trustee for a local charity, contributing his governance and leadership expertise to organisations that create meaningful impact. His analytical mindset and broad perspective help guide Green Genes through its early development with clarity, structure, and purpose.
Professor Paul Chazot FBPhS, Science Advisor, holds a Personal Chair in Pharmacology, Durham University (H factor=48). He is a Fellow of the British Pharmacological society, Past President, European Histamine Research Society, Fellow of the Durham Institute of Research, Development, and Invention, Northern Health Science Alliance (NHSA) Repurposing Medicines Network Representative, Academic Partner, Nevrargenics (www.nevrargenics.com), Vice Chair, EU COST action BM0806, Chair, International Union of Pharmacological Societies Subcommittee, Past Committee officer, British Neuroscience Association, Founder and Director, Wolfson Research Institute for Health an Wellbeing Pain Challenge Academy, International Concussion Alliance, Head for Change & Repercussion Groupings member. ARUK Research Committee; Durham Dementia Strategy Implementation Group member, Academic partner for www.livewellwithpain.co.uk and Company Director, Cerebrovia Therapeutics Ltd.
His research group focuses on the development of non-invasive imaging and biomarker diagnostic toolbox, and identification, characterisation and validation of novel drug targets, and a range of natural plant and synthetic drug-based, and infra-red light-based treatments for the major chronic CNS pathologies, and a first -line treatment for post-concussion syndrome.